Improved outcomes with radiation for prostate cancer

Hematology/Oncology Clinics of North America

Volumn 15, Issue 2, 2001, Pages 359-375

  Wallner, Kent ^b  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; HEALTH CARE COST; HUMAN; IMPOTENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROSTATITIS; QUALITY OF LIFE; RADIATION DOSE; RECTUM HEMORRHAGE; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME; URINE INCONTINENCE;

EID: 0035025847     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70217-3     Document Type: Article

References (34)

1. Status of radiation of prostate cancer at Stanford University
2. Transperineal percutaneous iodine-125 implantation for prostatic carcinoma using transrectal ultrasound and template guidance
3. Palladium-103 brachytherapy for prostate carcinoma
4. Simultaneous radiotherapy for prostate cancer: 125-Prostate implant followed by external-beam radiation
5. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
6. Prognostic role of serum prostatetic acid phosphatase for 103-Pd-based radiation for prostatic carcinoma
7. The effect of local control on metastatic dissemination in carcinoma of the prostate: Long-term results in patients treated with 125-I implantation
8. Nerve sparing radical prostatectomy: A different view
9. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation
10. Dose escalation with 3D conformal treatment: Five year outcomes, treatment optimization, and future directions
11. Patterns of care studies: Dose-response observations for local control of adenocarcinoma of the prostate
12. Clinical course of rectal complications following I-125 prostate brachytherapy
13. Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: Prognostic implications
14. Lateral rectal shielding reduces late rectal morbidity following high dose three-dimensional conformal radiation therapy for clinically localized prostate cancer: Further evidence for a significant dose effect
15. Efficacy of sildenafil citrate in prostate brachytherapy patients with erectile dysfunction
16. Prostate-specific antigen after anatomic radical retropubic prostatectomy
17. Sexual function following radical prostatectomy: Influence of preservation of neurovascular bundles
18. Fast neutron radiotherapy in the treatment of locally advanced adenocarcinoma of the prostate: Clinical experiences and future directions
19. Radiation therapy for clinically localized prostate cancer: A multi-institutional pooled analysis
20. Conformal proton therapy for early-stage prostate cancer
21. Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer
22. Long-term treatment-related complications of brachytherapy for early prostate cancer: A survey of treated patients
23. Patient-reported symptoms after primary therapy for early prostate cancer: Results of a prospective cohort study
24. Rectal bleeding after conformal 3D treatment of prostate cancer: Time to occurrence, response to treatment and duration of morbidity
25. Potency
26. Tumor control and morbidity following transperineal I-125 implantation for stage T1/T2 prostatic carcinoma
27. Retropubic implantation of iodine 125 in the treatment of prostatic cancer
28. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer
29. Efficacy of oral sildenafil in patients with erectile dysfunction after radiotherapy for carcinoma of the prostate
30. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer
31. Radical radiation therapy in the management of prostatic adenocarcinoma: The initial prostate specific antigen value as a predictor of treatment outcome